Involvement of Angiopoietin 2 and vascular endothelial growth factor in uveitis
PLOS ONE · 2023
DOI: 10.1371/journal.pone.0294745 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2023. Verfasst von Kayo Suzuki und 8 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine and Graduate School of Medicine, Department of Ophthalmology, Hokkaido University, Sapporo, Hokkaido, Japan. Hauptthemen laut MEDLINE: Autoimmune Diseases, Uveitis. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japanese Society for the Promotion of Science, Johnson & Johnson surgical vision, F. Hoffmann-La Roche Ltd.
Abstract (Originalsprache)
Purpose
Angiopoietin (Ang) 2 is released from vascular endothelial cells by the stimulation of vascular endothelial growth factor (VEGF)A. Ang2 increases the expression of leukocyte adhesion molecules on endothelial cells via nuclear factor κB. The aim of this study was to evaluate the effects of Ang2 and VEGFA on ocular autoimmune inflammation.
Methods
We measured the concentrations of Ang2 and VEGFA in vitreous samples among patients with uveitis. Vitreous samples were collected from 16 patients with idiopathic uveitis (uveitis group) and 16 patients with non-inflammatory eye disease (control group). Experimental autoimmune uveoretinitis (EAU) was induced in B10.BR mice with a human interphotoreceptor retinoid-binding protein-derived peptide. The retinochoroidal tissues of the EAU mice were removed, and the mRNA levels of Ang2 and VEGFA were examined. EAU mice treated with anti-Ang2, anti-VEGFA, a combination of anti-Ang2 and anti-VEGFA, anti-Ang2/VEGFA bispecific, or IgG control antibodies were clinically and histopathologically evaluated.
Results
The protein levels of Ang2 and VEGFA were significantly higher in the vitreous samples of patients with uveitis than in controls (P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Faculty of Medicine and Graduate School of Medicine, Department of Ophthalmology, Hokkaido University, Sapporo, Hokkaido, Japan.
- Department of Ophthalmology, Health Sciences University of Hokkaido, Sapporo, Hokkaido, Japan.
- Roche Pharma Research and Early Development, Roche Innovation Center, Basel, Switzerland.
ORCID-Profile: Daiju Iwata
Förderung
- Japanese Society for the Promotion of Science
- Johnson & Johnson surgical vision
- F. Hoffmann-La Roche Ltd
Zitieren
APA
Suzuki, K., Iwata, D., Namba, K., Hase, K., Hiraoka, M., Murata, M., Kitaichi, N., Foxton, R., & Ishida, S. (2023). Involvement of Angiopoietin 2 and vascular endothelial growth factor in uveitis. PLOS ONE. https://doi.org/10.1371/journal.pone.0294745
Vancouver
Suzuki K, Iwata D, Namba K, Hase K, Hiraoka M, Murata M, et al. Involvement of Angiopoietin 2 and vascular endothelial growth factor in uveitis. PLOS ONE. 2023. doi:10.1371/journal.pone.0294745
BibTeX
@article{Suzuki2023,
author = {Suzuki, Kayo and Iwata, Daiju and Namba, Kenichi and Hase, Keitaro and Hiraoka, Miki and Murata, Miyuki and Kitaichi, Nobuyoshi and Foxton, Richard and Ishida, Susumu},
title = {Involvement of Angiopoietin 2 and vascular endothelial growth factor in uveitis},
journal = {PLOS ONE},
year = {2023},
doi = {10.1371/journal.pone.0294745}
}
EUVIMED